My research involves the evaluation of experimental vaccines in human clinical trials. At the Center for Immunization Research, we have conducted numerous clinical trials of many different pediatric and adult candidate vaccines. These trials have included vaccines against HIV, hepatitis C, human papilloma virus, influenza, rotavirus, respiratory syncytial virus, dengue virus, and malaria. I am primarily interested in vaccines against dengue viruses and malaria have a very active dengue and malaria vaccine programs here at the Center for Immunization Research. An important interest of mine is studying the immunopathogenesis of dengue infection and disease. We hope to better understand the viral, host, and immunologic factors causing severe dengue illness by extensively characterizing the cellular and humoral responses of volunteers to live attenuated dengue virus vaccines. In addition to our clinical studies, my laboratory is also developing an animal model of dengue using rhesus macaques.

International Health, Dengue, Malaria, Vaccines

2005: National Institutes of Health Merit Award for outstanding basic and translational research in developing vaccines for the prevention of respiratory virus and flavivirus diseases

Durbin AP, McArthur JH, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, and Whitehead SS. Phase I Study of the Safety and Immunogenicity of rDEN4?30-200,201 a Live Attenuated Virus Vaccine Candidate for the Prevention of Dengue Serotype 4. Am J Trop Med Hyg 2008;79(5):678.

Durbin, A. P., M. J. Vargas, K. Wanionek, S. N. Hammond, A. Gordon, C. Rocha, A. Balmaseda, and E. Harris. 2008. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 2008;376:429-35.

Wu Y, Ellis RD, Shaffer D, Fontes, E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, and Durbin AP. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 2008;3:e2636.

Wright PF, Ankrah S, Henderson SE, Durbin AP, Speicher J, Whitehead SS, et al. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Vaccine 2008 Feb 13;26(7):882-90.

Whitehead SS, Blaney JE, Durbin AP and Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007;5:518-28.

Durbin, AP, McArthur JH, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, and Whitehead SS. 2006. rDEN2/4Delta30(ME), A Live Attenuated Chimeric Dengue Serotype 2 Vaccine Is Safe and Highly Immunogenic in Healthy Dengue-Naive Adults. Hum Vaccin 2(6):255-260.

Durbin, AP, McArthur JH, Marron JA, Blaney JE Jr., Thumar Wanionek K, Murphy BR, and Whitehead SS. 2006. The live attenuated dengue serotype 1 vaccine rDEN1?30 is safe and highly immunogenic in healthy adult volunteers. Human Vaccin 2(4):167-173.

Blaney JE, Jr., Durbin AP, Murphy BR and Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol 2006;19:10-32

Malkin, EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orbutt A, Awkal M, Zhou H, Want J, Stowers AW, Long CA, Mahanty S, Miller LH, Saul A, Durbin AP. Phase 1 clinical trial of apical membrane antigen 1 (AMA1): An asexual blood stage vaccine for Plasmodium flaciparum malaria. Infect. Immun. 2005:73(6);3677-3685

Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J,Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers AW, Miller LH, Saul A. Phase 1 Vaccine Trial of Pvs25H: A Transmission Blocking Vaccine for Plasmodium vivax Malaria. Vaccine 2005:23(24):3131-3138.

Durbin, AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr., Thumar B, Murphy BR, and Karron RA. rDEN4?30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis. 2005:191;710-718

Durbin AP, Karron RA, Thumar B, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS. A live attenuated dengue virus type 4 vaccine candidate with a 30 nucleotide deletion in the 3´ untranslated region is highly attenuated and immunogenic in humans. Am J Trop Med Hyg, 2001;65:405-413.

Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, Durbin AP, Murphy BR. A live attenuated dengue-4 virus vaccine candidate with a 30 base pair deletion in its 3´ untranslated region has restricted capacity for dissemination in mosquitoes and is not transmitted from vaccinees to mosquitoes. Am J Trop Med Hyg, 2001;65:414-419.

Durbin AP, Elkins WR, and Murphy BR. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types -1, -2,and -3 infection. Vaccine 2000;18:2462-2469.

Durbin AP, Skiadopoulos MH, McAuliffe JM, Riggs JM, Surman SR, Collins PL, and Murphy BR. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J Virol, 2000 Aug;74(15):6821-6831.

Tao T, Davoodi F, Cho CJ, Skiadopoulos, MH, Durbin AP, Collins PL, Murphy BR. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 2000;18:1359-1366.

Bailly JE, McAuliffe JM, Durbin AP, Elkins WR, Collins PL, Murphy BR. A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates. J Virol 2000;74(7):3188-3195.

Durbin AP, Cho CJ, Elkins WR, Wyatt LS, Moss B, Murphy BR. Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with that of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies. J Infect Dis 1999;179(6):1345-51.

Durbin AP, McAuliffe JM, Collins PL, Murphy BR. Mutations in the C, D and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates. Virology 1999;261:319-330.

Durbin AP, Hall SL, Siew JW, Whitehead SS, Collins PL, Murphy BR. Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology 1997;235:323-332.